| __timestamp | ACADIA Pharmaceuticals Inc. | Summit Therapeutics Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 32748000 | 6795238 |
| Thursday, January 1, 2015 | 90804000 | 7454247 |
| Friday, January 1, 2016 | 186456000 | 10345862 |
| Sunday, January 1, 2017 | 255062000 | 16984203 |
| Monday, January 1, 2018 | 265758000 | 16187290 |
| Tuesday, January 1, 2019 | 325638000 | 9299233.54 |
| Wednesday, January 1, 2020 | 388661000 | 19232000 |
| Friday, January 1, 2021 | 396028000 | 23611000 |
| Saturday, January 1, 2022 | 369090000 | 26700000 |
| Sunday, January 1, 2023 | 402466000 | 28215000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, ACADIA Pharmaceuticals Inc. and Summit Therapeutics Inc. have taken different paths in this regard. From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023. In contrast, Summit Therapeutics maintained a more conservative growth, with expenses increasing by approximately 315% over the same period. This stark difference highlights ACADIA's aggressive investment in administrative and sales functions, possibly to support rapid growth and expansion. Meanwhile, Summit's more restrained approach may reflect a focus on cost efficiency. As investors and stakeholders evaluate these companies, understanding their SG&A strategies provides valuable insights into their operational priorities and financial management.
SG&A Efficiency Analysis: Comparing AstraZeneca PLC and Summit Therapeutics Inc.
Gilead Sciences, Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Gilead Sciences, Inc. and ACADIA Pharmaceuticals Inc.
Cost Management Insights: SG&A Expenses for argenx SE and ACADIA Pharmaceuticals Inc.
Biogen Inc. vs Summit Therapeutics Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Genmab A/S vs Summit Therapeutics Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Madrigal Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Summit Therapeutics Inc. or Corcept Therapeutics Incorporated
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and PTC Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Summit Therapeutics Inc. and Geron Corporation
Operational Costs Compared: SG&A Analysis of Summit Therapeutics Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Viridian Therapeutics, Inc. Trends and Insights